BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24780540)

  • 1. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus.
    Nieminen MS; Altenberger J; Ben-Gal T; Böhmer A; Comin-Colet J; Dickstein K; Edes I; Fedele F; Fonseca C; García-González MJ; Giannakoulas G; Iakobishvili Z; Jääskeläinen P; Karavidas A; Kettner J; Kivikko M; Lund LH; Matskeplishvili ST; Metra M; Morandi F; Oliva F; Parkhomenko A; Parissis J; Pollesello P; Pölzl G; Schwinger RH; Segovia J; Seidel M; Vrtovec B; Wikström G
    Int J Cardiol; 2014 Jun; 174(2):360-7. PubMed ID: 24780540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
    Silvetti S; Nieminen MS
    Int J Cardiol; 2016 Jan; 202():138-43. PubMed ID: 26386941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
    Pölzl G; Altenberger J; Baholli L; Beltrán P; Borbély A; Comin-Colet J; Delgado JF; Fedele F; Fontana A; Fruhwald F; Giamouzis G; Giannakoulas G; Garcia-González MJ; Gustafsson F; Kaikkonen K; Kivikko M; Kubica J; von Lewinski D; Löfman I; Malfatto G; Manito N; Martínez-Sellés M; Masip J; Merkely B; Morandi F; Mølgaard H; Oliva F; Pantev E; Papp Z; Perna GP; Pfister R; Piazza V; Bover R; Rangel-Sousa D; Recio-Mayoral A; Reinecke A; Rieth A; Sarapohja T; Schmidt G; Seidel M; Störk S; Vrtovec B; Wikström G; Yerly P; Pollesello P
    Int J Cardiol; 2017 Sep; 243():389-395. PubMed ID: 28571618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden.
    Thorvaldsen T; Benson L; Hagerman I; Dahlström U; Edner M; Lund LH
    Int J Cardiol; 2014 Jul; 175(1):55-61. PubMed ID: 24820737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral levosimendan improves filling pressure and systolic function during long-term treatment.
    Jalanko M; Kivikko M; Harjola VP; Nieminen MS; Laine M
    Scand Cardiovasc J; 2011 Apr; 45(2):91-7. PubMed ID: 21348810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repetitive infusion of levosimendan in patients with chronic heart failure: a meta-analysis.
    Yi GY; Li JX; Zhang J; Niu LL; Zhang CY
    Med Sci Monit; 2015 Mar; 21():895-901. PubMed ID: 25811545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
    Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
    Mebazaa A; Erhardt L
    Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
    Sargento L; Brito D; Matias JS; Madeira H
    Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure.
    Parissis JT; Karavidas A; Bistola V; Arapi S; Paraskevaidis IA; Farmakis D; Korres D; Filippatos G; Matsakas E; Kremastinos DT
    Atherosclerosis; 2008 Mar; 197(1):278-82. PubMed ID: 17568589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
    Tasal A; Erturk M; Uyarel H; Karakurt H; Bacaksiz A; Vatankulu MA; Turfan M; Sonmez O; Erdogan E; Ergelen M
    J Cardiol; 2014 Jun; 63(6):418-23. PubMed ID: 24268422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival.
    Malfatto G; Della Rosa F; Villani A; Rella V; Branzi G; Facchini M; Parati G
    J Cardiovasc Pharmacol; 2012 Nov; 60(5):450-5. PubMed ID: 22932705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials.
    Silvetti S; Belletti A; Fontana A; Pollesello P
    ESC Heart Fail; 2017 Nov; 4(4):595-604. PubMed ID: 28834396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.
    Packer M; Colucci W; Fisher L; Massie BM; Teerlink JR; Young J; Padley RJ; Thakkar R; Delgado-Herrera L; Salon J; Garratt C; Huang B; Sarapohja T;
    JACC Heart Fail; 2013 Apr; 1(2):103-11. PubMed ID: 24621834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.